Drug makers leave the pain behind

August is a time for relaxing, holidaymaking and, apparently, culling unpromising pain projects. This month no fewer than five groups gave up on mid or late-stage agents for various intractable pain conditions, and this included one of the few big pharmas in this space, Lilly.